AIMS: Remote ischaemic conditioning (RIC) has been shown to reduce myocardial infarct size in patients. Our objective was to investigate whether the combination of RIC with either exenatide or glucose-insulin-potassium (GIK) is more effective than RIC alone. METHODS AND RESULTS: Pigs were submitted to 40 min of coronary occlusion followed by reperfusion, and received (i) no treatment, (ii) one of the following treatments: RIC (5 min ischemia/5 min reperfusion × 4), GIK, or exenatide (at doses reducing infarct size in clinical trials), or (iii) a combination of two of these treatments (RIC + GIK or RIC + exenatide). After 5 min of reperfusion (n = 4/group), prominent phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) was observed, both in control and reperfused myocardium, in animals receiving GIK, and mitochondria from these hearts showed reduced ADP-stimulated respiration. (1)H NMR-based metabonomics disclosed a shift towards increased glycolysis in GIK and exenatide groups. In contrast, oxidative stress (myocardial nitrotyrosine levels) and eNOS uncoupling were significantly reduced only by RIC. In additional experiments (n = 7-10/group), ANOVA demonstrated a significant effect of the number of treatments after 2 h of reperfusion on infarct size (triphenyltetrazolium, % of the area at risk; 59.21 ± 3.34, 36.64 ± 3.03, and 21.04 ± 2.38% for none, one, and two treatments, respectively), and significant differences between one and two treatments (P = 0.004) but not among individual treatments or between RIC + GIK and RIC + exenatide. CONCLUSIONS: GIK and exenatide activate cardioprotective pathways different from those of RIC, and have additive effects with RIC on infarct size reduction in pigs. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Remote ischaemic conditioning (RIC) has been shown to reduce myocardial infarct size in patients. Our objective was to investigate whether the combination of RIC with either exenatide or glucose-insulin-potassium (GIK) is more effective than RIC alone. METHODS AND RESULTS:Pigs were submitted to 40 min of coronary occlusion followed by reperfusion, and received (i) no treatment, (ii) one of the following treatments: RIC (5 min ischemia/5 min reperfusion × 4), GIK, or exenatide (at doses reducing infarct size in clinical trials), or (iii) a combination of two of these treatments (RIC + GIK or RIC + exenatide). After 5 min of reperfusion (n = 4/group), prominent phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) was observed, both in control and reperfused myocardium, in animals receiving GIK, and mitochondria from these hearts showed reduced ADP-stimulated respiration. (1)H NMR-based metabonomics disclosed a shift towards increased glycolysis in GIK and exenatide groups. In contrast, oxidative stress (myocardial nitrotyrosine levels) and eNOS uncoupling were significantly reduced only by RIC. In additional experiments (n = 7-10/group), ANOVA demonstrated a significant effect of the number of treatments after 2 h of reperfusion on infarct size (triphenyltetrazolium, % of the area at risk; 59.21 ± 3.34, 36.64 ± 3.03, and 21.04 ± 2.38% for none, one, and two treatments, respectively), and significant differences between one and two treatments (P = 0.004) but not among individual treatments or between RIC + GIK and RIC + exenatide. CONCLUSIONS: GIK and exenatide activate cardioprotective pathways different from those of RIC, and have additive effects with RIC on infarct size reduction in pigs. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Bruno García Del Blanco; Imanol Otaegui; José F Rodríguez-Palomares; Antoni Bayés-Genis; Eduard Fernández-Nofrerías; Victoria Vilalta Del Olmo; Xavier Carrillo; Borja Ibáñez; Fernando Worner; Juan Casanova; Eva Pueo; Jose R González-Juanatey; Javier López-Pais; Alfredo Bardají; Gil Bonet; Mónica Fuertes; Antonio Rodríguez-Sinovas; Marisol Ruiz-Meana; Javier Inserte; Ignasi Barba; Sandra Gómez-Talavera; Gerard Martí; Bernat Serra; Neus Bellera; Manuel Ojeda-Ramos; Hug Cuellar; Filipa Valente; Maria Ángeles Carmona; Elisabet Miró-Casas; Josep R Marsal; Antonia Sambola; Rosa M Lidón; Jordi Bañeras; Jaime Elízaga; Ferran Padilla; José A Barrabés; Derek J Hausenloy; Ignacio Ferreira-González; David García-Dorado Journal: Basic Res Cardiol Date: 2021-01-25 Impact factor: 17.165
Authors: Daniel I Bromage; Jack M J Pickard; Xavier Rossello; Oliver J Ziff; Niall Burke; Derek M Yellon; Sean M Davidson Journal: Cardiovasc Res Date: 2017-03-01 Impact factor: 10.787
Authors: Derek J Hausenloy; Hans Erik Bøtker; Peter Ferdinandy; Gerd Heusch; G André Ng; Andrew Redington; David Garcia-Dorado Journal: Cardiovasc Res Date: 2019-06-01 Impact factor: 10.787
Authors: Hector A Cabrera-Fuentes; Corina Alba-Alba; Julian Aragones; Jürgen Bernhagen; William A Boisvert; Hans E Bøtker; Gabriela Cesarman-Maus; Ingrid Fleming; David Garcia-Dorado; Sandrine Lecour; Elisa Liehn; Michael S Marber; Nephtali Marina; Manuel Mayr; Oscar Perez-Mendez; Tetsuji Miura; Marisol Ruiz-Meana; Eduardo M Salinas-Estefanon; Sang-Bing Ong; Hans J Schnittler; Jose T Sanchez-Vega; Adriana Sumoza-Toledo; Carl-Wilhelm Vogel; Dina Yarullina; Derek M Yellon; Klaus T Preissner; Derek J Hausenloy Journal: Basic Res Cardiol Date: 2015-12-14 Impact factor: 17.165
Authors: Tamás Baranyai; Csilla Terézia Nagy; Gábor Koncsos; Zsófia Onódi; Melinda Károlyi-Szabó; András Makkos; Zoltán V Varga; Péter Ferdinandy; Zoltán Giricz Journal: Cardiovasc Diabetol Date: 2015-11-18 Impact factor: 9.951